Clinical Trials Browser

Phase 2/3 × INDUSTRY × Thalidomide × Clear all

NCT00657488 2019-10-18

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase 2/3 Completed

Multiple Myeloma